All In Biotech

Drug Trial Radar · NCT05303701

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Moderate to Severe Alzheimer Disease

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Jul 2027

Primary completion

Jan 2028

Study completion Jul 2031

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).

Conditions

  • Moderate to Severe Alzheimer's Disease

Interventions

  • GV1001 PlaceboDrug

    0.9% normal saline

  • GV1001 1.12mgDrug

    Lyophilized peptide from hTERT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in SIB(Severe Impairment Battery) score after GV1001 administration for 24 weeksTime frame: Baseline, Week 26
  2. CIBIC-plus (Clinician Interview-Based Impression of Change-Plus) score after GV1001 administration for 24 weeksTime frame: Baseline, Week 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.